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A B S T R A C T
Humans and mice diﬀer substantially in their bile acid proﬁles as mice in addition to cholic acid (CA)
predominantly synthesize 6β-hydroxylated muricholic acids (MCAs) whereas humans produces chenodeoxy-
cholic acid (CDCA) and CA as primary bile acids. Identifying the gene performing 6β-hydroxylation would be
useful for ‘humanizing’ the bile acid proﬁle in mice for studies of the interaction between bile acids, gut
microbiota, and host metabolism. We investigated the formation of MCAs in primary murine hepatocytes and
found that αMCA is synthesized from CDCA and βMCA from UDCA. It is commonly assumed that the P450-
enzyme CYP3A11 catalyzes 6β-hydroxylation of bile acids, thus we hypothesized that mice without the Cyp3a11
gene would lack MCAs. To test this hypothesis, we analyzed bile acid proﬁles in Cyp3a deﬁcient mice, which lack
7 genes in the Cyp3a gene cluster including Cyp3a11, and compared them with wild-type littermate controls. Bile
acid composition in liver, gallbladder, caecum and serum from Cyp3a knock out mice and wild-type littermate
controls was analyzed with UPLC-MS/MS and revealed no major diﬀerences in bile acid composition. We
conclude that Cyp3a11 is not necessary for 6β-hydroxylation and the formation of MCAs.
1. Introduction
Bile acids are important signalling molecules that bind to and
activate nuclear and membrane receptors involved in a large number of
metabolic processes [1–4]. Farnesoid X receptor (FXR) is the most
studied bile acid nuclear receptor and is eﬃciently activated by
chenodeoxycholic acid (CDCA) and cholic acid (CA). It regulates
metabolism of bile acids, lipids, and glucose and is therefore an
attractive target for the treatment of metabolic diseases [5].
Bile acid-dependent regulation of metabolism via FXR has been
widely studied in various mouse models but substantial diﬀerences
between murine and human bile acid proﬁles limit the translation of
ﬁndings into human pathophysiology. Speciﬁcally, besides diﬀerent
preferences in the formation of glycine or taurine conjugates, mice
synthesize alpha- and betamuricholic acids (α/βMCA) in addition to
chenodeoxycholic acid and cholic acid (CDCA and CA), which are the
primary bile acids found in humans. The taurine conjugates of the MC
As (Tα/βMCA) have been identiﬁed by us and others as potent FXR
antagonists [6,7]. Germ-free mice, which can be used to study the
interaction between human bacteria and bile acids when colonized with
human microbiota, have higher levels of MCAs (speciﬁcally TβMCA)
than conventionally raised mice. Ideal mouse models for the study of
human gut microbiota and bile acid-regulated metabolism and diseases
would be mice with a human bile acid proﬁle, i.e. with TCDCA instead
of Tα/βMCA.
It has been suggested that the mouse liver generates αMCA by 6β-
hydroxylation of CDCA and that βMCA is generated by further 7β-
epimerization of αMCA [8–10]. Another possible pathway for βMCA
formation could be 6β-hydroxylation of ursodeoxycholic acid (UDCA),
which is the 7β-isomer of CDCA and a primary bile acid in mice [6].
The P450-enzyme CYP3A11 is commonly presented as bile acid 6β-
hydroxylase [11–13]; however, its involvement in the synthesis of
murine bile has never been proven. In this study, we hypothesized that
mice without Cyp3a11 would lack murine bile acids and thus could
potentially be an improved model for studies of bile acid-dependent
metabolism. To investigate if Cyp3a11 is required for the synthesis of
murine bile acids we used a commercially available mouse strain with
deletion of 7 genes in the Cyp3a gene cluster including Cyp3a11.
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2. Materials and methods
2.1. Isolation of primary hepatocytes
Primary murine hepatocytes were isolated using a modiﬁed protocol
from Zhang at al. [14]. Twelve week-old female C57BL/6 mice were
anesthetized with isoﬂurane and the liver was perfused through the
portal vein ﬁrst with wash buﬀer (HBSS, with 0.5 mM EGTA and 25 mM
HEPES) and then with digestion buﬀer (DMEM supplemented with
100 U/mL Penicillin, 0.1 mg/mL Streptomycin, 15 mM HEPES and
100 U/mL of collagenase Type IV, Sigma Aldrich) for 15 min.
After suﬃcient digestion, the gallbladder was removed and the liver
cells were liberated in a petri dish containing digestion medium. The
cell suspension was then ﬁltered through a 70 µm cell strainer, washed
3 times by centrifugation at 50g for 3 min, and re-suspended in culture
medium (DMEM/F12 with 5% Penicillin and Streptomycin and 10%
FBS). Viability was assessed by trypan blue; viability was> 90% for all
cell preparations. Hepatocytes were plated on collagen-coated (Type I
collagen; BD) plates and allowed to attach for 4 h at 37 °C in a
humidiﬁed 5% CO2 incubator. Cells were washed once with culture
medium and then switched to an FBS-free culture medium.
2.2. Bile acid experiments in vitro
Isolated primary murine hepatocytes were plated in 12-well plates
(400,000 cells/mL). After 2 h, when the cells were attached, the
medium was removed and 2 mL fresh medium together with 20 µl
deuterium (d4)-labeled CDCA or UDCA (d4-CDCA or d4-UDCA, solved
in DMSO) or DMSO alone were added to the cells. The ﬁnal concentra-
tion of d4-bile acids in the wells were 25 µM for CDCA and 100 µM for
UDCA. The cells were incubated for 24 h and then 100 µl of the medium
was taken for bile acid analysis to determine the proﬁle of d4-labeled
bile acids.
2.3. Design of mouse experiments
Mice with a deletion of 7 genes (Cyp3a11, Cyp3a16, Cyp3a25,
Cyp3a41, Cyp3a44, Cyp3a57, and Cyp3a59) in the Cyp3a gene cluster
(Cyp3a KO) were purchased from Taconic, Model 8841. The mice were
bred with C57/Bl6 wild-type mice for at least two generations to obtain
homozygous Cyp3a KO mice and wild-type littermate controls. All mice
were 10–14 weeks at the time of the analysis. First, blood was taken
from portal and caval veins under deep isoﬂurane anesthesia. Next, the
mice were killed and tissues (liver, gallbladder and caecum) were
harvested. Whole body, liver, gallbladder, and caecum were weighed
and all tissues were frozen in liquid nitrogen and stored at−80 °C until
further analyzed. All experiments were performed using protocols
approved by the University of Gothenburg Animal Studies Committee.
2.4. Bile acid analysis
Bile acids in liver, gallbladder, caecum and serum from portal and
caval veins were analyzed using ultra-performance liquid chromato-
graphy-tandem mass spectrometry (UPLC-MS/MS) and quantiﬁed using
a combination of unlabeled standards and d4-labeled internal standards
as previously described [15]. This methodology was also used for
measurement of hepatic 7alpha-hydroxy-4-cholesten-3-one (C4) as
marker of bile acid synthesis. The whole gallbladder, approximately
50 mg of liver and caecum, and 25 µl serum was used for the analyses.
2.5. Quantitative real-time PCR
Approximately 30 mg of liver was homogenized using TissueLyzer
(Qiagen) and total RNA was isolated using RNeasy kit (Qiagen).
Conditions for qPCR and primer sequences were previously described
[6]. Assays were performed in a 7900HT Fast Real-Time PCR System
(Applied Biosystems) or CFX96 Real-Time System (Bio-Rad Labora-
tories). The reactions were analyzed using the ΔΔCT analysis method.
2.6. Preparation of liver microsomes
Liver biopsies were homogenized in 800 µl lysis buﬀer (100 mM
Triethylammoinium bicarbonate (TEAB), 255 mM Sucrose, 10 mM EDT
A) with a Tissuelyser for 3 min (25 Hz). The homogenate were ﬁrst
centrifuged in +4 °C for 5 min (500g) and the supernatants were
transferred to new tubes and centrifuged for 20 min (20 000g) in
+4 °C. 500 µl of the supernatants were then transferred to a Thick
walled Beckman Coulter centrifuge tube (No 343778) prewashed with
TEAB and ultra-centrifuged for 60 min (160,000g). The supernatants
were discarded and the pellets were washed 3 times with TEAB
(100 mM) and then resuspended in 200 µl lysis buﬀer (200 mM
TEAB, 8 M Urea, 4% CHAPS, 0.1%SDS).
Fig. 1. Formation of murine bile acids in primary murine hepatocytes. (A-B)
Concentrations of d4-labeled bile acids (µM) in medium collected from primary
hepatocytes incubated with d4-CDCA (25 µM) (A) and d4-UDCA (100 µM) (B) for 24 h.
Primary hepatocytes were isolated from two individual mice and plated in triplicates;
CDCA, chenodeoxycholic acid; MCA, muricholic acid; UDCA, ursodeoxycholic acid; G,
glycine-conjugated species; T, taurine-conjugated species.
A. Wahlström et al. Biochemistry and Biophysics Reports 10 (2017) 70–75
71
2.7. Proteomics analysis of liver microsomal samples
2.7.1. Sample preparation and digestion
The samples were homogenized by sonication in 200 µl lysis buﬀer
(200 mM Triethylammoinium bicarbonate (TEAB), 8 M Urea, 4%
CHAPS, 0.1%SDS). Total protein concentration was determined with
Pierce™ Pierce 660 nm Protein Assay Reagent (Thermo Scientiﬁc).
Samples from the diﬀerent groups were pooled three and three
resulting in two samples for each group. Aliquots containing 100 μg
of each sample and 100 µg of a reference pool containing equal
amounts of all samples were in solution digested with trypsin. Brieﬂy,
TEAB (100 mM) was added to a ﬁnal volume of 90 µl, samples were
reduced with 1 mM TCEP at 37 °C for 60 min and alkylated with 2 mM
methyl methane thiosulfonate in RT for 20 min. Trypsin (Promega,
Sequencing grade) was added in a ratio of 1:20 relative to protein
amount and incubated overnight at 37 °C. Digested peptides were
labeled using TMT 6-plex isobaric mass tagging reagents (Thermo
Scientiﬁc) according to the manufacturer instructions. In a set, samples
from all groups and the reference, were labeled with a unique tag from
a TMT 6plex isobaric mass tag labeling kit. After TMT labeling, the
samples in a set were pooled resulting in two independent sets in total
to cover all samples.
The peptides were further puriﬁed and fractionated into
seventeen fractions by Strong Cation Exchange Chromatography (ÄKT
A-system, Amersham-Pharmacia) on a PolySULFOETHYL A™ column
(100×2.1 mm, 5 µm 300 Å, PolyLC inc.) from 20% to 40% B over
40 min. Solvent A was 25 mM ammonium formate, pH 2.8 and solvent
B was 500 mM ammonium formate, pH 2.8.
2.7.2. LC-MS/MS analysis and database search
Each fraction was desalted using PepClean C18 spin columns
(Thermo Fisher Scientiﬁc) according to the manufacturer's guidelines.
Samples were analyzed on an LTQ-Orbitrap Velos mass spectrometer
interfaced to an Easy-nLC (Thermo Fisher Scientiﬁc). Peptides were
separated on a C18 analytical column (200×0.075 mm I.D, 3 µm Dr.
Maisch, Germany) over a 80 min gradient from 5% to 40% acetonitrile
in 0.1% formic acid. The MS scans was performed at the resolution
30,000 with a mass range of m/z 400–1800. MS/MS analysis was
performed in a data-dependent mode at 7500 in resolution and m/z
100–2000, with the top ten most abundant doubly or multiply charged
precursor ions in each MS scan selected for MS/MS fragmentation.
For relative quantiﬁcation, identiﬁcation and annotation the MS
raw data ﬁles for each TMT set were merged in the search using
Proteome Discoverer version 1.4 (Thermo Fisher Scientiﬁc). The
database search was performed with the Mascot search engine
(Matrix Science) against Mus musculus Swissprot Database version
November 2012 (Swiss Institute of Bioinformatics, Switzerland). The
data was searched with MS peptide tolerance of 10 ppm and MS/MS
tolerance for identiﬁcation of 0.5 Da. Tryptic peptides were accepted
with 1 missed cleavage and variable modiﬁcations of methionine
oxidation, cysteine methylthiolation and ﬁxed modiﬁcations of N-
terminal TMT6plex and lysine TMT6plex were selected. The detected
peptide threshold in the software was set to 1% False Discovery Rate by
searching against a reversed database and identiﬁed proteins were
grouped by sharing the same sequences to minimize redundancy. Only
peptides unique for a given protein were considered for relative
quantitation, excluding those common to other isoforms or proteins
of the same family.
3. Results and discussion
3.1. Formation of αMCA from CDCA and βMCA from UDCA in primary
murine hepatocytes
To investigate if MCAs are synthesized from CDCA or UDCA we
incubated primary murine hepatocytes isolated from wild-type C57Bl6/
J mice with d4-CDCA or d4-UDCA, and analyzed d4-labeled bile acids
in the culture media after 24 h. We found that the media from
Fig. 2. Characterization of Cyp3a KO mice. (A-C) Body weight (A) and relative liver (B) and gallbladder (C) weight in female and male Cyp3a KO and wild-type mice. (D) Gene
expression of Cyp3a11 in livers from female and male Cyp3a KO and wild-type mice. Mean values± SEM are plotted; n=5–11 mice or samples/group; * P<0.05, ** P< 0.01, *** P<
0.001**** P< 0.0001 indicate diﬀerences between female Cyp3a KO and wild-type or male Cyp3a KO and wild-type mice analyzed with unpaired t-test.
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hepatocytes incubated with d4-CDCA contained signiﬁcant amounts of
d4-αMCA and d4-TCDCA but no βMCA (Fig. 1A). In contrast, incuba-
tion with d4-UDCA generated d4-βMCA and d4-TUDCA but no d4-αMC
A. Thus, βMCA is generated, at least in part, by 6β-hydroxylation
of UDCA and not from CDCA, which commonly has been suggested
[11–13].
3.2. Cyp3aKO mice have a largely normal phenotype and produce murine
bile acids
There were no apparent diﬀerences in the phenotype between the
Cyp3a KO mice and their wild-type littermates. Body weight and
gallbladder weights did not diﬀer but relative liver weights were
slightly increased in the male Cyp3a KO mice compared with their
wild-type controls (48.2±1.0 versus 44.5±1.2 mg/g body weight,
p=0.04; Fig. 2A-C). Analysis of Cyp3a11 gene expression in liver
showed that Cyp3a11 was absent, verifying that Cyp3a11 was success-
fully deleted in the Cyp3a KO mice (Fig. 2D).
To determine if deletion of the Cyp3a gene cluster would aﬀect bile
acid composition we analyzed bile acid levels in liver, gallbladder,
caecum and serum from portal and caval veins. Total bile acid levels
were unchanged in all the analyzed compartments and there were only
minor changes in the amounts of speciﬁc bile acids (Table 1,
Supplemental Tables 1–3). In male Cyp3a KO mice, we found a slight
decrease of TαMCA in the gallbladder whereas the levels of TβMCA
were unchanged (Table 1). In liver and caecum there were no
diﬀerences in the amount of TαMCA or TβMCA (Table 1,
Supplemental Table 1). In serum from portal and caval veins, there
were no signiﬁcant changes in any bile acid, and there was rather a
tendency towards higher levels of both TαMCA and TβMCA in Cyp3a
KO mice (Supplemental Tables 2–3). These ﬁndings show that Cyp3a-
deﬁcient mice still synthesize normal amounts of murine bile acids.
It has been described that mouse liver in contrast to human liver can
re-hydroxylate DCA into CA [16]. To investigate if the livers of Cyp3a-
deﬁcient mice have reduced capacity to re-hydroxylate DCA we
calculated the hepatic ratio between total DCA (TDCA+DCA) and total
CA (TCA+CA). The Cyp3a KO mice had similar hepatic total DCA/total
CA ratios as the wild-type control mice, which indicates that deletion of
the genes in the Cyp3a gene cluster does not aﬀect 7α-rehydroxylation
of DCA (Table 1). In line with the minor changes in bile acid levels we
found similar expression of the bile acid synthetic genes involved in the
classical (neutral) and alternative (acidic) pathways of bile acid
synthesis (Cyp7a1, Cyp8b1, Cyp27a1 and Cyp7b1) in Cyp3a KO and
wild-type control mice (Fig. 3A-D), which is also reﬂected by similar
hepatic C4 levels (Table 1). The only signiﬁcant diﬀerence was a small
increase in Cyp27a1 expression in the female Cyp3a KO mice (Fig. 3C).
Our study show that Cyp3a11 is not essential for the formation of
murine bile acids. This is in agreement with a very recent study by
Takahashi et al., which showed that mice without the Cyp3a gene
cluster produce normal amounts of MCAs and suggested that Cyp2c70 is
responsible for the species diﬀerences in bile acid metabolism between
mice and humans [17]. To investigate if the expression of Cyp2c70 is
elevated in germ-free mice, since they have increased levels of MCAs,
we evaluated expression data from a previous microarray study
performed in our group. Indeed, germ-free mice show higher expression
of the Cyp2c70 gene than conventionally raised mice [18]. In contrast,
the expression of Cyp3a11 was signiﬁcantly lower in the germ-free mice
supporting the dispensability of CYP3A11 in MCA formation. We also
found a similar trend towards lower CYP3A11 and higher CYP2C70
levels in germ-free mice using proteomics (Fig. S1A-B).
Furthermore, we show that βMCA is generated from 6β-hydroxyla-
tion of UDCA in vitro and that synthesis of αMCA does not need to
precede βMCA formation (Fig. 1A-B). This is an important ﬁnding and
provides a new insight about the formation of bile acids. Takahashi
et al. indicated that epimerization of αMCA to βMCA might occur in the
mouse intestine by gut microbes [17] but our previous data suggest that
at least some βMCA is produced in the liver since germ-free mice have
higher levels of TβMCA compared with conventionally raised mice [6].
Table 1
Bile acid composition in liver and gallbladder. Liver (pmol/mg tissue) and gallbladder (nmol/mg tissue) bile acids in female and male Cyp3a KO and wild type mice.
Liver bile acids (pmol/mg tissue) Cyp3a KO females Cyp3a WT females Cyp3a KO males Cyp3a WT males
TαMCA 13.6± 3.9 8.4± 1.2 7.2± 1.1 8.0±1.3
TβMCA 38.2± 9.4 26.8± 6.1 13.4± 2.6 18.6± 3.2
TωMCA 19.8± 3.9 11.4± 1.9 11.7± 1.4 11.4± 1.6
TCA 73.2± 16.1 69.1± 12.7 34.5± 2.5 54.8± 9.4
TCDCA 2.7±0.5 2.0± 0.1 1.7± 0.2 1.5±0.2
TDCA 5.3±0.7 7.5± 1.3 6.6± 1.3 7.3±1.3
TUDCA 2.1±0.5 1.6± 0.16 1.6± 0.6 1.2±0.30
TLCA traces traces 0.2± 0.0 traces
αMCA traces traces traces
βMCA 0.4±0.1 0.3± 0.1 0.2± 0.1 0.2±0.0
ωMCA 0.4±0.1 traces 0.3± 0.0 0.2±0.0
CA 1.2±0.4 0.7± 0.2 0.6± 0.1 0.6±0.1
Total bile acids 156.8± 35.7 127.9±23.8 77.9± 10.1 103.8± 17.6
C4 0.5±0.1 0.4± 0.1 0.2± 0.0 0.2±0.0
total DCA/total CA ratio 0.1± 0.0 0.1± 0.0 0.2± 0.0 0.2± 0.0
Gallbladder bile acids (nmol/
mg tissue)
Cyp3a KO females Cyp3a WT females Cyp3a KO males Cyp3a WT males
TαMCA 9.7± 1.6 7.5± 1.5 12.0± 1.3 7.4±0.5 **
TβMCA 18.8±2.2 17.7±2.7 15.3± 2.4 12.5± 1.1
TωMCA 9.8± 1.0 6.3± 0.7 10.4± 1.4 7.5±0.6
TCA 67.1±4.3 55.2±7.3 58.6± 6.7 56.7± 3.6
TCDCA 1.3± 0.2 0.8± 0.2 1.3±0.2 0.7±0.1
TDCA 1.5± 0.2 1.7± 0.2 2.2±0.1 2.3±0.2
TUDCA 1.0± 0.2 0.9± 0.2 1.1±0.1 0.6±0.1 **
CA 0.9± 0.3 0.6± 0.2 1.1±0.1 1.1±0.3
Total bile acids 110.0± 10.0 90.7±12.9 102.0± 12.4 88.9± 6.5
Data are presented as mean values± SEM; n=5–11 mice/group; * P< 0.05, ** P<0.01, *** P< 0.001**** P< 0.0001 indicate diﬀerences between female Cyp3a KO and wild type or
male Cyp3a KO and wild type mice SEM analyzed with multiple t-test with correction using the Holm-Sidak method.; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic
acid; LCA, lithocholic acid; MCA, muricholic acid; UDCA, ursodeoxycholic acid; T, taurine-conjugated species; C4, 7α-hydroxy-cholestene-4-one.
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UDCA can be synthesized in the liver with 7-keto-LCA as a potential
intermediate (Fig. 4). Several studies have shown that 7-keto-LCA is
formed by gut bacteria with 7-hydroxysteroid dehydrogenase activity
[19–21]. Other studies have shown that 7-keto-LCA is converted to
CDCA and UDCA [22,23] and studies with human and murine
liver microsomes characterized 11β-hydroxysteroid dehydrogenase 1
Fig. 3. Expression of genes involved in bile acid synthesis. (A-D) Expression of cytochrome P450 genes Cyp7a1 (A), Cyp8b1 (B), Cyp27a1 (C) and Cyp7b1 (D) in livers from female and
male Cyp3a KO and wild-type mice. Mean values± SEM are plotted; n=5–11 mice or samples/group; * P< 0.05, ** P<0.01, *** P< 0.001**** P< 0.0001 indicate diﬀerences
between female Cyp3a KO and wild-type or male Cyp3a KO and wild-type mice analyzed with unpaired t-test.
Fig. 4. Synthesis of murine bile acids in mice. 7-Keto-LCA is an intermediate between CDCA and UDCA produced by bacteria with 7α/β-hydroxysteroid dehydrogenases (7α/βHSDs).
7-Keto-LCA can be converted to CDCA or UDCA by 11β-hydroxysteroid dehydrogenase1 (11βHSD1) in the liver. Our in vitro experiments showed that αMCA and βMCA can be
synthesized from CDCA and UDCA, respectively. Further experiments are required to investigate if UDCA can be produced by an alternative pathway and if epimerization between αMCA
and βMCA can occur in the liver and/or in the intestine by the gut microbiota.
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(11β-HSD1) as the responsible enzyme [24,25]. The conversion of CDC
A to UDCA might occur in the mouse liver and this reaction is then
likely to precede the formation of βMCA (Fig. 4). However, our in vitro
experiments with primary murine hepatocytes did not show conversion
from CDCA to UDCA and only traces of 7-keto-LCA (Fig. 1A). This,
together with our previous ﬁndings that UDCA is a primary bile acid in
mice and can be produced in the absence of bacteria, suggests that UDC
A might be formed by an alternative pathway in the mouse liver
(Fig. 4).
In the future, Cyp2c70 KO mice may become an attractive “huma-
nized” animal model for studies of bile acid-regulated metabolism and
it would be important to investigate if germ-free Cyp2c70 KO mice also
lack the murine bile acids and have a human bile acid proﬁle.
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